AGFAGDDAPR is a bioactive peptide that is a competitive and orally effective inhibitor of dipeptidyl peptidase-IV ( DPP-IV ). AGFAGDDAPR can enhance the level of GLP-1 in the body by inhibiting DPP-IV, thereby stimulating insulin secretion, improving β-cell function, and inhibiting abnormal proliferation of α-cells, exerting anti-diabetic effects. AGFAGDDAPR can be used for research on type 2 diabetes [1].
References:
[1]. Lu Y, et al. A Novel Dipeptidyl Peptidase IV Inhibitory Tea Peptide Improves Pancreatic β-Cell Function and Reduces α-Cell Proliferation in Streptozotocin-Induced Diabetic Mice. Int J Mol Sci. 2019 Jan 14;20(2):322.
References:
[1]. Lu Y, et al. A Novel Dipeptidyl Peptidase IV Inhibitory Tea Peptide Improves Pancreatic β-Cell Function and Reduces α-Cell Proliferation in Streptozotocin-Induced Diabetic Mice. Int J Mol Sci. 2019 Jan 14;20(2):322.